Gonorrhoea

April 23, 2025

Recent advancements in the treatment of gonorrhoea have emerged with the introduction of a new oral antibiotic, gepotidacin. This drug has shown promising results in clinical trials, effectively combating the increasingly resistant strains of gonorrhoea. Health authorities express concern over the rising difficulty in treating this sexually transmitted infection.

About Gonorrhoea

Gonorrhoea is a common sexually transmitted infection caused by bacterium, Neisseria gonorrhoeae.
It spreads through unprotected sexual activities, including vaginal, oral, and anal sex.
Many women may not exhibit symptoms, making it challenging to detect early.
Untreated gonorrhoea can lead to severe health complications, including infertility and chronic pelvic pain, and increases the risk of HIV transmission.

Gepotidacin Clinical Trial

The clinical trial involved 628 participants diagnosed with uncomplicated gonorrhoea. Participants were divided into two groups – one received two doses of oral gepotidacin, while the other was treated with the standard dual therapy of ceftriaxone and azithromycin. The results indicated that gepotidacin cured 93% of cases, closely matching the 91% cure rate of the standard treatment.

Mechanism of Action

Gepotidacin operates differently from traditional antibiotics. It inhibits the bacterial DNA replication process. This unique mechanism allows it to remain effective against strains resistant to common treatments. The drug demonstrated complete efficacy against rectal gonorrhoea, although it was less effective for throat infections, achieving a 78% cure rate compared to 94% for the standard treatment.

Side Effects

Participants reported mild side effects, including nausea and diarrhoea, but no serious adverse reactions were noted. The safety profile of gepotidacin appears favourable, but ongoing monitoring is essential to address any potential long-term effects.

Antibiotic Resistance

The UK is currently experiencing a rise in antibiotic-resistant gonorrhoea cases. Reports indicate 17 instances of ceftriaxone-resistant gonorrhoea from January 2024 to March 2025. Experts warn that the overuse of gepotidacin could lead to similar resistance patterns. Continuous monitoring and responsible use of this new treatment are critical to preserving its effectiveness.

Importance of Prevention and Testing

While gepotidacin offers a new hope in treating gonorrhoea, health experts stress the importance of STI prevention and regular testing. Individuals with new or casual partners are encouraged to seek testing to mitigate the spread of infections. The development of additional treatment options remains crucial in the fight against antimicrobial resistance.

« Previous Post